Transcriptional targeting to brain cells: Engineering cell type-specific promoter containing cassettes for enhanced transgene expression

Advanced Drug Delivery Reviews

Volumn 61, Issue 7-8, 2009, Pages 589-602

  Boulaire, Jérôme ^a   Balani, Poonam ^a   Wang, Shu ^a,b  

^a INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Gene expression cassette; Gene therapy; Neural cell specific promoter; Targeted gene transfer

Indexed keywords

BRAIN CELLS; CELL TYPES; CIS-ACTING ELEMENT; ENGINEERING CELLS; GENE EXPRESSION CASSETTE; GENE THERAPY; LOW LEVEL; NEURAL CELL-SPECIFIC PROMOTER; TARGET CELLS; TARGETED GENE TRANSFER; THERAPEUTIC EFFICACY; TRANSGENE EXPRESSION;

BIOACTIVITY; GENE EXPRESSION; GENE TRANSFER; INTERNET; MAMMALS; PATIENT TREATMENT;

CELLS;

CIS ACTING ELEMENT; VIRUS PROTEIN;

ADENO ASSOCIATED VIRUS; BRAIN CELL; CELL TYPE; GENE CASSETTE; GENE EXPRESSION; GENE THERAPY; HEPATITIS VIRUS; HUMAN CYTOMEGALOVIRUS; INVERTED TERMINAL REPEAT; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TRANSCRIPTION INITIATION; TRANSGENE;

ANIMALS; BRAIN; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC ENGINEERING; HUMANS; NEURONS; PROMOTER REGIONS, GENETIC; TRANSCRIPTIONAL ACTIVATION; TRANSGENES;

EID: 65749119189     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.02.007     Document Type: Review

References (149)

1. Lim K.L., and Lim T.M. Molecular mechanisms of neurodegeneration in Parkinson's disease: clues from Mendelian syndromes. IUBMB Life 55 (2003) 315-322
2. During M.J., and Ashenden L.M. Towards gene therapy for the central nervous system. Mol. Med. Today 4 (1998) 485-493
3. Mandel R.J., Rendahl K.G., Snyder R.O., and Leff S.E. Progress in direct striatal delivery of L-dopa via gene therapy for treatment of Parkinson's disease using recombinant adeno-associated viral vectors. Exp. Neurol. 159 (1999) 47-64
4. Costantini L.C., Bakowska J.C., Breakefield X.O., and Isacson O. Gene therapy in the CNS. Gene Ther. 7 (2000) 93-109
5. Davidson B.L., and Breakefield X.O. Viral vectors for gene delivery to the nervous system. Nat. Rev., Neurosci. 4 (2003) 353-364
6. Ryan D.A., and Federoff H.J. Translational considerations for CNS gene therapy. Expert Opin. Biol. Ther. 7 (2007) 305-318
7. Benitez J.A., and Segovia J. Gene therapy targeting in the central nervous system. Curr. Gene Ther. 3 (2003) 127-145
8. Miller N., and Vile R. Targeted vectors for gene therapy. FASEB J. 9 (1995) 190-199
9. Miller N., and Whelan J. Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Hum. Gene Ther. 8 (1997) 803-815
10. Nettelbeck D.M., Jerome V., and Muller R. A strategy for enhancing the transcriptional activity of weak cell type-specific promoters. Gene Ther. 5 (1998) 1656-1664
11. Weeratna R.D., Wu T., Efler S.M., Zhang L., and Davis H.L. Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters. Gene Ther. 8 (2001) 1872-1878
12. Lemon B., and Tjian R. Orchestrated response: a symphony of transcription factors for gene control. Genes Dev. 14 (2000) 2551-2569
13. Emerson B.M. Specificity of gene regulation. Cell 109 (2002) 267-270
14. Orphanides G., and Reinberg D. A unified theory of gene expression. Cell 108 (2002) 439-451
15. Pennacchio L.A., and Rubin E.M. Genomic strategies to identify mammalian regulatory sequences. Nat. Rev., Genet. 2 (2001) 100-109
16. Fitzsimons H.L., Bland R.J., and During M.J. Promoters and regulatory elements that improve adeno-associated virus transgene expression in the brain. Methods 28 (2002) 227-236
17. Paterna J.C., and Bueler H. Recombinant adeno-associated virus vector design and gene expression in the mammalian brain. Methods 28 (2002) 208-218
18. Kugler S. Neuron-specific expression of therapeutic proteins: evaluation of different cellular promoters in recombinant adenoviral vectors. Mol. Cell. Neurosci. 17 (2001) 78-96
19. Glover C.P., Bienemann A.S., Heywood D.J., Cosgrave A.S., and Uney J.B. Adenoviral-mediated, high-level, cell-specific transgene expression: a SYN1-WPRE cassette mediates increased transgene expression with no loss of neuron specificity. Mol. Ther. 5 (2002) 509-516
20. Forss-Petter S., Danielson P.E., Catsicas S., Battenberg E., Price J., Nerenberg M., and Sutcliffe J.G. Transgenic mice expressing beta-galactosidase in mature neurons under neuron-specific enolase promoter control. Neuron 5 (1990) 187-197
21. Twyman R.M., and Jones E.A. Sequences in the proximal 5' flanking region of the rat neuron-specific enolase (NSE) gene are sufficient for cell type-specific reporter gene expression. J. Mol. Neurosci. 8 (1997) 63-73
22. Schoch S., Cibelli G., and Thiel G. Neuron-specific gene expression of synapsin I. Major role of a negative regulatory mechanism. J. Biol. Chem. 271 (1996) 3317-3323
23. Sasahara M. PDGF B-chain in neurons of the central nervous system, posterior pituitary, and in a transgenic model. Cell 64 (1991) 217-227
24. Games D. Alzheimer-type neuropathology in transgenic mice over-expressing V717F beta-amyloid precursor protein. Nature 373 (1995) 523-527
25. Sasahara M., Fries J.W., Raines E.W., Gown A.M., Westrum L.E., Frosch M.P., Bonthron D.T., Ross R., and Collins T. PDGF B-chain in neurons of the central nervous system, posterior pituitary, and in a transgenic model. Cell 64 (1991) 217-227
26. Paterna J.C., Moccetti T., Mura A., Feldon J., and Bueler H. Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain. Gene Ther. 7 (2000) 1304-1311
27. Peel A.L., Zolotukhin S., Schrimsher G.W., Muzyczka N., and Reier P.J. Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Ther. 4 (1997) 16-24
28. Khachigian L.M. Novel cis-acting elements in the human platelet-derived growth factor B-chain core promoter that mediate gene expression in cultured vascular endothelial cells. J. Biol. Chem. 269 (1994) 22647-22656
29. Khachigian L.M., Resnick N., Gimbrone M.J., and Collins T.J. Nuclear factor-kappa B interacts functionally with the platelet-derived growth factor B-chain shear-stress response element in vascular endothelial cells exposed to fluid shear stress. J. Clin. Invest. 96 (1995) 1169-1175
30. Liang Y. Transcriptional regulation of the SIS//PDGF-B gene in human osteosarcoma cells by the Sp family of transcription factors. J. Biol. Chem. 271 (1996) 11792-11797
31. Rafty L.A., and Khachigian L.M. Zinc finger transcription factors mediate high constitutive platelet-derived growth factor-B expression in smooth muscle cells derived from aortae of newborn rats. J. Biol. Chem. 273 (1998) 5758-5764
32. Hoyle G.W., Mercer E.H., Palmiter R.D., and Brinster R.L. Cell-specific expression from the human dopamine beta-hydroxylase promoter in transgenic mice is controlled via a combination of positive and negative regulatory elements. J. Neurosci. 14 (1994) 2455-2463
33. Oh M.S., Hong S.J., Huh Y., and Kim K.S. Expression of transgenes in midbrain dopamine neurons using the tyrosine hydroxylase promoter. Gene Ther. 16 (2009) 437-440
34. Kim S.M., Yang J.W., Park M.J., Lee J.K., Kim S.U., Lee Y.S., and Lee M.A. Regulation of human tyrosine hydroxylase gene by neuron-restrictive silencer factor. Biochem. Biophys. Res. Commun. 346 (2006) 426-435
35. Ghee M., Baker H., Miller J.C., and Ziff E.B. AP-1, CREB and CBP transcription factors differentially regulate the tyrosine hydroxylase gene. Brain Res. Mol. Brain Res. 55 (1998) 101-114
36. Trocme C., Sarkis C., Hermel J.M., Duchateau R., Harrison S., Simonneau M., Al-Shawi R., and Mallet J. CRE and TRE sequences of the rat tyrosine hydroxylase promoter are required for TH basal expression in adult mice but not in the embryo. Eur. J. Neurosci. 10 (1998) 508-521
37. Sasaoka T., Kobayashi K., Nagatsu I., Takahashi R., Kimura M., Yokoyama M., Nomura T., Katsuki M., and Nagatsu T. Analysis of the human tyrosine hydroxylase promoter-chloramphenicol acetyltransferase chimeric gene expression in transgenic mice. Brain Res. Mol. Brain Res. 16 (1992) 274-286
38. Schimmel J.J., Crews L., Roffler-Tarlov S., and Chikaraishi D.M. 4.5 kb of the rat tyrosine hydroxylase 5' flanking sequence directs tissue specific expression during development and contains consensus sites for multiple transcription factors. Brain Res. Mol. Brain Res. 74 (1999) 1-14
39. Gandelman K.Y., Coker III G.T., Moffat M., and O'Malley K.L. Species and regional differences in the expression of cell-type specific elements at the human and rat tyrosine hydroxylase gene loci. J. Neurochem. 55 (1990) 2149-2152
40. Wong S.C., Moffat M.A., Coker G.T., Merlie J.P., and O'Malley K.L. The 3' flanking region of the human tyrosine hydroxylase gene directs reporter gene expression in peripheral neuroendocrine tissues. J. Neurochem. 65 (1995) 23-31
41. Afar R., Silverman R., Aguanno A., and Albert V.R. Positive and negative elements contribute to the cell-specific expression of the rat dopamine beta-hydroxylase gene. Brain Res. Mol. Brain Res. 36 (1996) 79-92
42. Ishiguro H., Kim K.S., and Joh T.H. Identification of a negative regulatory element in the 5'-flanking region of the human dopamine beta-hydroxylase gene. Brain Res. Mol. Brain Res. 34 (1995) 251-261
43. Su M., Hu H., Lee Y., d'Azzo A., Messing A., and Brenner M. Expression specificity of GFAP transgenes. Neurochem. Res. 29 (2004) 2075-2093
44. Brenner M. Structure and transcriptional regulation of the GFAP gene. Brain Pathol. 4 (1994) 245-257
45. Brenner M., Kisseberth W.C., Su Y., Besnard F., and Messing A. GFAP promoter directs astrocyte-specific expression in transgenic mice. J. Neurosci. 14 (1994) 1030-1037
46. Lee Y., Messing A., Su M., and Brenner M. GFAP promoter elements required for region-specific and astrocyte-specific expression. Glia 56 (2008) 481-493
47. Wrabetz L., Taveggia C., Feltri M.L., Quattrini A., Awatramani R., Scherer S.S., Messing A., and Kamholz J. A minimal human MBP promoter-lacZ transgene is appropriately regulated in developing brain and after optic enucleation, but not in shiverer mutant mice. J. Neurobiol. 34 (1998) 10-26
48. Chen H., McCarty D.M., Bruce A.T., and Suzuki K. Gene transfer and expression in oligodendrocytes under the control of myelin basic protein transcriptional control region mediated by adeno-associated virus. Gene Ther. 5 (1998) 50-58
49. Chen H., McCarty D.M., Bruce A.T., and Suzuki K. Oligodendrocyte-specific gene expression in mouse brain: use of a myelin-forming cell type-specific promoter in an adeno-associated virus. J. Neurosci. Res. 55 (1999) 504-513
50. McIver S.R., Lee C.S., Lee J.M., Green S.H., Sands M.S., Snider B.J., and Goldberg M.P. Lentiviral transduction of murine oligodendrocytes in vivo. J. Neurosci. Res. 82 (2005) 397-403
51. Jin B.K., Belloni M., Conti B., Federoff H.J., Starr R., Son J.H., Baker H., and Joh T.H. Prolonged in vivo gene expression driven by a tyrosine hydroxylase promoter in a defective herpes simplex virus amplicon vector. Hum. Gene Ther. 7 (1996) 2015-2024
52. Xia C.F., Boado R.J., Zhang Y., Chu C., and Pardridge W.M. Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter. J. Gene Med. 10 (2008) 306-315
53. Kuroda H., Kutner R.H., Bazan N.G., and Reiser J. A comparative analysis of constitutive and cell-specific promoters in the adult mouse hippocampus using lentivirus vector-mediated gene transfer. J. Gene Med. 10 (2008) 1163-1175
54. Foldvary N., Bingaman W.E., and Wyllie E. Surgical treatment of epilepsy. Neurol. Clin. 19 (2001) 491-515
55. Tenenbaum L., Chtarto A., Lehtonen E., Velu T., Brotchi J., and Levivier M. Recombinant AAV-mediated gene delivery to the central nervous system. J. Gene. Med. 6 Suppl 1 (2004) S212-222
56. Vezzani A., Sperk G., and Colmers W.F. Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci. 22 (1999) 25-30
57. Vezzani A., and Sperk G. Overexpression of NPY and Y2 receptors in epileptic brain tissue: an endogenous neuroprotective mechanism in temporal lobe epilepsy?. Neuropeptides 38 (2004) 245-252
58. Richichi C., Lin E.J., Stefanin D., Colella D., Ravizza T., Grignaschi G., Veglianese P., Sperk G., During M.J., and Vezzani A. Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J. Neurosci. 24 (2004) 3051-3059
59. Lin E.J., Richichi C., Young D., Baer K., Vezzani A., and During M.J. Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development. Eur. J. Neurosci. 18 (2003) 2087-2092
60. Chhatwal J.P., Hammack S.E., Jasnow A.M., Rainnie D.G., and Ressler K.J. Identification of cell-type-specific promoters within the brain using lentiviral vectors. Gene Ther. 14 (2007) 575-583
61. Virta S., Rapola J., Jalanko A., and Laine M. Use of nonviral promoters in adenovirus-mediated gene therapy: reduction of lysosomal storage in the aspartylglucosaminuria mouse. J. Gene Med. 8 (2006) 699-706
62. Besnard F., Brenner M., Nakatani Y., Chao R., Purohit H.J., and Freese E. Multiple interacting sites regulate astrocyte-specific transcription of the human gene for glial fibrillary acidic protein. J. Biol. Chem. 266 (1991) 18877-18883
63. de Leeuw B., Su M., ter Horst M., Iwata S., Rodijk M., Hoeben R.C., Messing A., Smitt P.S., and Brenner M. Increased glia-specific transgene expression with glial fibrillary acidic protein promoters containing multiple enhancer elements. J. Neurosci. Res. 83 (2006) 744-753
64. Hwang D.Y., Carlezon Jr. W.A., Isacson O., and Kim K.S. A high-efficiency synthetic promoter that drives transgene expression selectively in noradrenergic neurons. Hum. Gene Ther. 12 (2001) 1731-1740
65. Hwang D.Y., Hwang M.M., Kim H.S., and Kim K.S. Genetically engineered dopamine beta-hydroxylase gene promoters with better PHOX2-binding sites drive significantly enhanced transgene expression in a noradrenergic cell-specific manner. Mol. Ther. 11 (2005) 132-141
66. Edelman G.M., Meech R., Owens G.C., and Jones F.S. Synthetic promoter elements obtained by nucleotide sequence variation and selection for activity. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 3038-3043
67. Zhang G.R., Wang X., Yang T., Sun M., Zhang W., Wang Y., and Geller A.I. A tyrosine hydroxylase-neurofilament chimeric promoter enhances long-term expression in rat forebrain neurons from helper virus-free HSV-1 vectors. Brain Res. Mol. Brain Res. 84 (2000) 17-31
68. Kaplitt M.G., Kwong A.D., Kleopoulos S.P., Mobbs C.V., Rabkin S.D., and Pfaff D.W. Preproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 8979-8983
69. Song S., Wang Y., Bak S.Y., Lang P., Ullrey D., Neve R.L., O'Malley K.L., and Geller A.I. An HSV-1 vector containing the rat tyrosine hydroxylase promoter enhances both long-term and cell type-specific expression in the midbrain. J. Neurochem. 68 (1997) 1792-1803
70. Gao Q., Sun M., Wang X., and Geller A.I. Isolation of an enhancer from the rat tyrosine hydroxylase promoter that supports long-term, neuronal-specific expression from a neurofilament promoter, in a helper virus-free HSV-1 vector system. Brain Res. 1130 (2007) 1-16
71. Wang X., Kong L., Zhang G.R., Sun M., and Geller A.I. A preproenkephalin-neurofilament chimeric promoter in a helper virus-free herpes simplex virus vector enhances long-term expression in the rat striatum. Neurobiol. Dis. 16 (2004) 596-603
72. Nettelbeck D.M., Jerome V., and Muller R. Gene therapy: designer promoters for tumour targeting. Trends Genet. 16 (2000) 174-181
73. Iyer M., Wu L., Carey M., Wang Y., Smallwood A., and Gambhir S.S. Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 14595-14600
74. Iyer M. Noninvasive imaging of enhanced prostate-specific gene expression using a two-step transcriptional amplification-based lentivirus vector. Mol. Ther. 10 (2004) 545-552
75. Iyer M. Non-invasive imaging of a transgenic mouse model using a prostate-specific two-step transcriptional amplification strategy. Transgenic Res. 14 (2005) 47-55
76. Sato M., Johnson M., Zhang L., Gambhir S.S., Carey M., and Wu L. Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer. Clin. Cancer Res. 11 (2005) 3743-3749
77. Fang B., Ji L., Bouvet M., and Roth J.A. Evaluation of GAL4/TATA in vivo: induction of transgene expression by adenovirally mediated gene codelivery. J. Biol. Chem. 273 (1998) 4972-4975
78. Segawa T., Takebayashi H., Kakehi Y., Yoshida O., Narumiya S., and Kakizuka A. Prostate-specific amplification of expanded polyglutamine expression: a novel approach for cancer gene therapy. Cancer Res. 58 (1998) 2282-2287
79. Koch P.E., Guo Z.S., Kagawa S., Gu J., Roth J.A., and Fang B. Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system. Mol. Ther. 3 (2001) 278-283
80. Zhang D., Sutanto E.N., and Rakoczy P.E. Concurrent enhancement of transcriptional activity and specificity of a retinal pigment epithelial cell-preferential promoter. Mol. Vis. 10 (2004) 208-214
81. Liu B.H., Paton J.F., and Kasparov S. Viral vectors based on bidirectional cell-specific mammalian promoters and transcriptional amplification strategy for use in vitro and in vivo. BMC Biotechnol. 8 (2008) 49
82. Liu B.H., Yang Y., Paton J.F., Li F., Boulaire J., Kasparov S., and Wang S. GAL4-NF-kappaB fusion protein augments transgene expression from neuronal promoters in the rat brain. Mol. Ther. 14 (2006) 872-882
83. Kaltschmidt C., Kaltschmidt B., and Baeuerle P.A. Stimulation of ionotropic glutamate receptors activates transcription factor NF-kappa B in primary neurons. Proc. Natl. Acad. Sci. USA 92 (1995) 9618-9622
84. Bhakar A.L. Constitutive nuclear factor-kappa B activity is required for central neuron survival. J. Neurosci. 22 (2002) 8466-8475
85. Mattson M.P. NF-kappaB in the survival and plasticity of neurons. Neurochem. Res. 30 (2005) 883-893
86. Meffert M.K., and Baltimore D. Physiological functions for brain NF-kappaB. Trends Neurosci. 28 (2005) 37-43
87. Fridmacher V. Forebrain-specific neuronal inhibition of nuclear factor-kappaB activity leads to loss of neuroprotection. J. Neurosci. 23 (2003) 9403-9408
88. Liu B., Wang S., Brenner M., Paton J.F., and Kasparov S. Enhancement of cell-specific transgene expression from a Tet-Off regulatory system using a transcriptional amplification strategy in the rat brain. J. Gene Med. 10 (2008) 583-592
89. Kaczmarczyk S.J., and Green J.E. A single vector containing modified cre recombinase and LOX recombination sequences for inducible tissue-specific amplification of gene expression. Nucleic Acids Res. 29 (2001) e56
90. Livet J., Weissman T.A., Kang H., Draft R.W., Lu J., and Bennis R.A. Transgenic strategies for combinatorial expression of fluorescent proteins in the nervous system. Nature 450 (2007) 56-62
91. Namikawa K., Murakami K., Okamoto T., Okado H., and Kiyama H. A newly modified SCG10 promoter and Cre/loxP-mediated gene amplification system achieve highly specific neuronal expression in animal brains. Gene Ther. 13 (2006) 1244-1250
92. Maeda M., Namikawa K., Kobayashi I., Ohba N., Takahara Y., Kadono C., Tanaka A., and Kiyama H. Targeted gene therapy toward astrocytoma using a Cre/loxP-based adenovirus system. Brain Res. 1081 (2006) 34-43
93. Loonstra A., Vooijs M., Beverloo H.B., Allak B.A., van Drunen E., Kanaar R., Berns A., and Jonkers J. Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9209-9214
94. Pfeifer A., Brandon E.P., Kootstra N., Gage F.H., and Verma I.M. Delivery of the Cre recombinase by a self-deleting lentiviral vector: efficient gene targeting in vivo. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 11450-11455
95. Silver D.P., and Livingston D.M. Self-excising retroviral vectors encoding the Cre recombinase overcome Cre-mediated cellular toxicity. Mol. Cell 8 (2001) 233-243
96. Baba Y., Nakano M., Yamada Y., Saito I., and Kanegae Y. Practical range of effective dose for Cre recombinase-expressing recombinant adenovirus without cell toxicity in mammalian cells. Microbiol. Immunol. 49 (2005) 559-570
97. Kaspar B.K., Vissel B., Bengoechea T., Crone S., Randolph-Moore L., Muller R., Brandon E.P., Schaffer D., Verma I.M., Lee K.F., Heinemann S.F., and Gage F.H. Adeno-associated virus effectively mediates conditional gene modification in the brain. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 2320-2325
98. Boshart M., Weber F., Jahn G., Dorsch-Hasler K., Fleckenstein B., and Schaffner W. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 41 (1985) 521-530
99. Niwa H., Yamamura K., and Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108 (1991) 193-199
100. Kobayashi M., Tanaka A., Hayashi Y., and Shimamura S. The CMV enhancer stimulates expression of foreign genes from the human EF-1 alpha promoter. Anal. Biochem. 247 (1997) 179-181
101. Barnhart K.M., Hartikka J., Manthorpe M., Norman J., and Hobart P. Enhancer and promoter chimeras in plasmids designed for intramuscular injection: a comparative in vivo and in vitro study. Hum. Gene Ther. 9 (1998) 2545-2553
102. Hagstrom J.N., Couto L.B., Scallan C., Burton M., McCleland M.L., Fields P.A., Arruda V.R., Herzog R.W., and High K.A. Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter. Blood 95 (2000) 2536-2542
103. Xu L., Daly T., Gao C., Flotte T.R., Song S., Byrne B.J., Sands M.S., and Parker Ponder K. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum. Gene Ther. 12 (2001) 563-573
104. Yew N.S., Przybylska M., Ziegler R.J., Liu D., and Cheng S.H. High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter. Mol. Ther. 4 (2001) 75-82
105. Davis J.J., Wang L., Dong F., Zhang L., Guo W., Teraishi F., Xu K., Ji L., and Fang B. Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter. Cancer Gene Ther. 13 (2006) 720-723
106. Gruh I., Wunderlich S., Winkler M., Schwanke K., Heinke J., Blomer U., Ruhparwar A., Rohde B., Li R.K., Haverich A., and Martin U. Human CMV immediate-early enhancer: a useful tool to enhance cell-type-specific expression from lentiviral vectors. J. Gene Med. 10 (2008) 21-32
107. Xu Z.L., Mizuguchi H., Ishii-Watabe A., Uchida E., Mayumi T., and Hayakawa T. Optimization of transcriptional regulatory elements for constructing plasmid vectors. Gene 272 (2001) 149-156
108. Liu B.H., Wang X., Ma Y.X., and Wang S. CMV enhancer/human PDGF-beta promoter for neuron-specific transgene expression. Gene Ther. 11 (2004) 52-60
109. Wang C.Y., Guo H.Y., Lim T.M., Ng Y.K., Neo H.P., Hwang P.Y., Yee W.C., and Wang S. Improved neuronal transgene expression from an AAV-2 vector with a hybrid CMV enhancer/PDGF-beta promoter. J. Gene Med. 7 (2005) 945-955
110. Li Y., Wang X., Guo H., and Wang S. Axonal transport of recombinant baculovirus vectors. Mol. Ther. 10 (2004) 1121-1129
111. Li Y., Yang Y., and Wang S. Neuronal gene transfer by baculovirus-derived vectors accommodating a neurone-specific promoter. Exp. Physiol. 90 (2005) 39-44
112. Wang C.Y., and Wang S. Astrocytic expression of transgene in the rat brain mediated by baculovirus vectors containing an astrocyte-specific promoter. Gene Ther. 13 (2006) 1447-1456
113. Hioki H., Kameda H., Nakamura H., Okunomiya T., Ohira K., Nakamura K., Kuroda M., Furuta T., and Kaneko T. Efficient gene transduction of neurons by lentivirus with enhanced neuron-specific promoters. Gene Ther. 14 (2007) 872-882
114. Duale H., Kasparov S., Paton J.F., and Teschemacher A.G. Differences in transductional tropism of adenoviral and lentiviral vectors in the rat brainstem. Exp. Physiol. 90 (2005) 71-78
115. Lonergan T., Teschemacher A.G., Hwang D.Y., Kim K.S., Pickering A.E., and Kasparov S. Targeting brain stem centers of cardiovascular control using adenoviral vectors: impact of promoters on transgene expression. Physiol. Genomics 20 (2005) 165-172
116. Nakai H., Montini E., Fuess S., Storm T.A., Meuse L., Finegold M., Grompe M., and Kay M.A. Helper-independent and AAV-ITR-independent chromosomal integration of double-stranded linear DNA vectors in mice. Mol. Ther. 7 (2003) 101-111
117. McCarty D.M., Young Jr. S.M., and Samulski R.J. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu. Rev. Genet. 38 (2004) 819-845
118. Xiao X., Xiao W., Li J., and Samulski R.J. A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle. J. Virol. 71 (1997) 941-948
119. Yang C.C., Xiao X., Zhu X., Ansardi D.C., Epstein N.D., Frey M.R., Matera A.G., and Samulski R.J. Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro. J. Virol. 71 (1997) 9231-9247
120. Philpott N.J., Giraud-Wali C., Dupuis C., Gomos J., Hamilton H., Berns K.I., and Falck-Pedersen E. Efficient integration of recombinant adeno-associated virus DNA vectors requires a p5-rep sequence in cis. J. Virol. 76 (2002) 5411-5421
121. Duan D., Sharma P., Yang J., Yue Y., Dudus L., Zhang Y., Fisher K.J., and Engelhardt J.F. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J. Virol. 72 (1998) 8568-8577
122. Yang J., Zhou W., Zhang Y., Zidon T., Ritchie T., and Engelhardt J.F. Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J. Virol. 73 (1999) 9468-9477
123. Philip R., Brunette E., Kilinski L., Murugesh D., McNally M.A., Ucar K., Rosenblatt J., Okarma T.B., and Lebkowski J.S. Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes. Mol. Cell. Biol. 14 (1994) 2411-2418
124. Vieweg J., Boczkowski D., Roberson K.M., Edwards D.W., Philip M., Philip R., Rudoll T., Smith C., Robertson C., and Gilboa E. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res. 55 (1995) 2366-2372
125. Johnston K.M., Jacoby D., Pechan P.A., Fraefel C., Borghesani P., Schuback D., Dunn R.J., Smith F.I., and Breakefield X.O. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum. Gene Ther. 8 (1997) 359-370
126. Lam P., Hui K.M., Wang Y., Allen P.D., Louis D.N., Yuan C.J., and Breakefield X.O. Dynamics of transgene expression in human glioblastoma cells mediated by herpes simplex virus/adeno-associated virus amplicon vectors. Hum. Gene Ther. 13 (2002) 2147-2159
127. Fu Y., Wang Y., and Evans S.M. Viral sequences enable efficient and tissue-specific expression of transgenes in Xenopus. Nat. Biotechnol. 16 (1998) 253-257
128. Hsiao C.D., Hsieh F.J., and Tsai H.J. Enhanced expression and stable transmission of transgenes flanked by inverted terminal repeats from adeno-associated virus in zebrafish. Dev. Dyn. 220 (2001) 323-336
129. Wang C.Y., and Wang S. Adeno-associated virus inverted terminal repeats improve neuronal transgene expression mediated by baculoviral vectors in rat brain. Hum. Gene Ther. 16 (2005) 1219-1226
130. Costantini L.C., Jacoby D.R., Wang S., Fraefel C., Breakefield X.O., and Isacson O. Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors. Hum. Gene Ther. 10 (1999) 2481-2494
131. Chou C.Y., Horng L.S., and Tsai H.J. Uniform GFP-expression in transgenic medaka (Oryzias latipes) at the F0 generation. Transgenic Res. 10 (2001) 303-315
132. Xin K.Q., Ooki T., Jounai N., Mizukami H., Hamajima K., Kojima Y., Ohba K., Toda Y., Hirai S., Klinman D.M., Ozawa K., and Okuda K. A DNA vaccine containing inverted terminal repeats from adeno-associated virus increases immunity to HIV. J. Gene Med. 5 (2003) 438-445
133. Chikhlikar P., Barros de Arruda L., Agrawal S., Byrne B., Guggino W., August J.T., and Marques Jr. E.T. Inverted terminal repeat sequences of adeno-associated virus enhance the antibody and CD8(+) responses to a HIV-1 p55Gag/LAMP DNA vaccine chimera. Virology 323 (2004) 220-232
134. Brooks A.R., Harkins R.N., Wang P., Qian H.S., Liu P., and Rubanyi G.M. Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J. Gene Med. 6 (2004) 395-404
135. Flotte T.R., Afione S.A., Solow R., Drumm M.L., Markakis D., Guggino W.B., Zeitlin P.L., and Carter B.J. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J. Biol. Chem. 268 (1993) 3781-3790
136. Donello J.E., Loeb J.E., and Hope T.J. Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J. Virol. 72 (1998) 5085-5092
137. Higashimoto T., Urbinati F., Perumbeti A., Jiang G., Zarzuela A., Chang L.J., Kohn D.B., and Malik P. The woodchuck hepatitis virus post-transcriptional regulatory element reduces readthrough transcription from retroviral vectors. Gene Ther. 14 (2007) 1298-1304
138. Loeb J.E., Cordier W.S., Harris M.E., Weitzman M.D., and Hope T.J. Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: implications for gene therapy. Hum. Gene Ther. 10 (1999) 2295-2305
139. Xu Z.L., Mizuguchi H., Mayumi T., and Hayakawa T. Woodchuck hepatitis virus post-transcriptional regulation element enhances transgene expression from adenovirus vectors. Biochim. Biophys. Acta 1621 (2003) 266-271
140. Glover C.P., Bienemann A.S., Hopton M., Harding T.C., Kew J.N., and Uney J.B. Long-term transgene expression can be mediated in the brain by adenoviral vectors when powerful neuron-specific promoters are used. J. Gene Med. 5 (2003) 554-559
141. Sims K., Ahmed Z., Gonzalez A.M., Read M.L., Cooper-Charles L., Berry M., and Logan A. Targeting adenoviral transgene expression to neurons. Mol. Cell. Neurosci. 39 (2008) 411-417
142. Mahonen A.J., Airenne K.J., Purola S., Peltomaa E., Kaikkonen M.U., Riekkinen M.S., Heikura T., Kinnunen K., Roschier M.M., Wirth T., and Yla-Herttuala S. Post-transcriptional regulatory element boosts baculovirus-mediated gene expression in vertebrate cells. J. Biotechnol. 131 (2007) 1-8
143. Zeng J., Du J., Zhao Y., Palanisamy N., and Wang S. Baculoviral vector-mediated transient and stable transgene expression in human embryonic stem cells. Stem Cells 25 (2007) 1055-1061
144. Xu R., Janson C.G., Mastakov M., Lawlor P., Young D., Mouravlev A., Fitzsimons H., Choi K.L., Ma H., Dragunow M., Leone P., Chen Q., Dicker B., and During M.J. Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes. Gene Ther. 8 (2001) 1323-1332
145. Klein R.L., Hamby M.E., Gong Y., Hirko A.C., Wang S., Hughes J.A., King M.A., and Meyer E.M. Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain. Exp. Neurol. 176 (2002) 66-74
146. Shevtsova Z., Malik J.M., Michel U., Bahr M., and Kugler S. Promoters and serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo. Exp. Physiol. 90 (2005) 53-59
147. Boulos S., Meloni B.P., Arthur P.G., Bojarski C., and Knuckey N.W. Assessment of CMV, RSV and SYN1 promoters and the woodchuck post-transcriptional regulatory element in adenovirus vectors for transgene expression in cortical neuronal cultures. Brain Res. 1102 (2006) 27-38
148. Brun S., Faucon-Biguet N., and Mallet J. Optimization of transgene expression at the posttranscriptional level in neural cells: implications for gene therapy. Mol. Ther. 7 (2003) 782-789
149. Recillas-Targa F., Valadez-Graham V., and Farrell C.M. Prospects and implications of using chromatin insulators in gene therapy and transgenesis. Bioessays 26 (2004) 796-807